Why Investors Should Love Pfizer's Acquisition of Trillium - NewsBreak
By Hernandez in Business
Updated 3 years ago
Pfizer plans to acquire Trillium Therapeutics for nearly $2.3 billion. Trillium's pipeline fits really well with Pfizer's oncology programs. The price tag of the transaction also seems reasonable. Pfizer (NYSE:PFE) announced in August that it plans to acquire Trillium Therapeutics (NASDAQ:TRIL) for nearly $2.3 billion. In this Motley Fool Live...
